NAS:PACB (USA) Also trade in: Germany

Pacific Biosciences of California Inc

$ 6.91 0 (0%)
Volume: 1,907,390 Avg Vol (1m): 1,456,718
Market Cap $: 1.05 Bil Enterprise Value $: 987.06 Mil
P/E (TTM): 0.00 P/B: 11.02
Earnings Power Value -4.63
Net Current Asset Value 0.14
Tangible Book 0.63
Projected FCF -3.34
Median P/S Value 3.71
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 5.55
Cash-To-Debt ranked higher than
53.64% of 261 companies
in the Diagnostics & Research industry.
Industry Max: 32990, Med: 3.52, Min: 0.01
PACB: 5.55
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 3.41, Med: 7.31, Max: 10000
Current: 5.55
3.41
10000
Equity-to-Asset 0.51
Equity-to-Asset ranked lower than
52.30% of 239 companies
in the Diagnostics & Research industry.
Industry Max: 0.97, Med: 0.61, Min: -2.81
PACB: 0.51
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -2.1, Med: 0.64, Max: 0.92
Current: 0.51
-2.1
0.92
Debt-to-Equity 0.16
Debt-to-Equity ranked higher than
67.07% of 164 companies
in the Diagnostics & Research industry.
Industry Max: 22.86, Med: 0.36, Min: 0.01
PACB: 0.16
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.01, Med: 0.15, Max: 0.43
Current: 0.16
-0.01
0.43
Debt-to-EBITDA -0.15
Debt-to-EBITDA ranked lower than
100.00% of 116 companies
in the Diagnostics & Research industry.
Industry Max: 77.72, Med: 1.77, Min: 0.03
PACB: -0.15
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.6, Med: -0.17, Max: -0.02
Current: -0.15
-0.6
-0.02
Piotroski F-Score 2
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.38
DISTRESS
GREY
SAFE
Beneish M-Score -0.91
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -340.76%
WACC 8.69%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -141.60
Operating Margin ranked lower than
72.31% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 53.36, Med: -0.59, Min: -70300
PACB: -141.6
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -65237.04, Med: -201.8, Max: -31.4
Current: -141.6
-65237.04
-31.4
Net Margin % -143.62
Net Margin ranked lower than
72.61% of 241 companies
in the Diagnostics & Research industry.
Industry Max: 41.13, Med: -2.48, Min: -119600
PACB: -143.62
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -64965.19, Med: -205.91, Max: -34.16
Current: -143.62
-64965.19
-34.16
ROE % -102.75
ROE ranked lower than
83.06% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 61.7, Med: -6.75, Min: -12038.19
PACB: -102.75
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -272.85, Med: -94.02, Max: -46.42
Current: -102.75
-272.85
-46.42
ROA % -65.27
ROA ranked lower than
76.72% of 262 companies
in the Diagnostics & Research industry.
Industry Max: 1174.65, Med: -4.54, Min: -1248.4
PACB: -65.27
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -81.89, Med: -57.48, Max: -24.81
Current: -65.27
-81.89
-24.81
ROC (Joel Greenblatt) % -257.83
ROC (Joel Greenblatt) ranked lower than
69.50% of 259 companies
in the Diagnostics & Research industry.
Industry Max: 17601.65, Med: -9.57, Min: -3842027.78
PACB: -257.83
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1441.77, Med: -632.19, Max: -236.94
Current: -257.83
-1441.77
-236.94
3-Year Total Revenue Growth Rate -5.40
3-Year Revenue Growth Rate ranked lower than
63.19% of 182 companies
in the Diagnostics & Research industry.
Industry Max: 371, Med: 4.8, Min: -100
PACB: -22
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -22, Med: 15.8, Max: 38.8
Current: -22
-22
38.8
3-Year Total EBITDA Growth Rate -54.70
3-Year EBITDA Growth Rate ranked lower than
62.36% of 178 companies
in the Diagnostics & Research industry.
Industry Max: 141.7, Med: 10.1, Min: -340.1
PACB: -27.5
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -27.5, Med: 32.25, Max: 78.8
Current: -27.5
-27.5
78.8
3-Year EPS w/o NRI Growth Rate -21.90
3-Year EPS w/o NRI Growth Rate ranked lower than
62.58% of 163 companies
in the Diagnostics & Research industry.
Industry Max: 138.7, Med: 10.1, Min: -301
PACB: -21.9
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» PACB's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:PACB

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Diagnostics & Research    NAICS : 334516    SIC : 3826
Compare SHSE:603127 NAS:AXDX NAS:CDNA SHSE:603108 TSE:4694 SZSE:300685 SHSE:600055 NAS:NTRA NSE:LALPATHLAB NAS:NRC NAS:VREX NAS:LNTH NAS:FLDM OSTO:SECT B SZSE:300406 HKSE:01763 OSTO:CEVI SZSE:300439 TSE:4282 NAS:TWST
Traded in other countries P09.Germany
Address 1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Ratios

Current vs industry vs history
PB Ratio 11.02
PB Ratio ranked higher than
53.88% of 245 companies
in the Diagnostics & Research industry.
Industry Max: 270, Med: 4.02, Min: 0.15
PACB: 11.02
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.52, Med: 4.65, Max: 19.08
Current: 11.02
0.52
19.08
PS Ratio 12.80
PS Ratio ranked higher than
56.96% of 230 companies
in the Diagnostics & Research industry.
Industry Max: 6350, Med: 3.81, Min: 0.07
PACB: 12.8
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 2, Med: 6.9, Max: 28.58
Current: 12.8
2
28.58
EV-to-EBIT -9.31
EV-to-EBIT ranked lower than
100.00% of 118 companies
in the Diagnostics & Research industry.
Industry Max: 341.21, Med: 25.06, Min: 5.74
PACB: -9.31
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -33.7, Med: -4.05, Max: 0.5
Current: -9.31
-33.7
0.5
EV-to-EBITDA -9.95
EV-to-EBITDA ranked lower than
100.00% of 132 companies
in the Diagnostics & Research industry.
Industry Max: 486.47, Med: 20.75, Min: 3.94
PACB: -9.95
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -38.7, Med: -4.3, Max: 0.6
Current: -9.95
-38.7
0.6
EV-to-Revenue 13.05
EV-to-Revenue ranked higher than
59.50% of 242 companies
in the Diagnostics & Research industry.
Industry Max: 19679, Med: 4.24, Min: 0.09
PACB: 13.05
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -2.7, Med: 5.6, Max: 378.4
Current: 13.05
-2.7
378.4
Current Ratio 2.50
Current Ratio ranked higher than
64.40% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.58, Min: 0.02
PACB: 2.5
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 2.22, Med: 5.01, Max: 22.74
Current: 2.5
2.22
22.74
Quick Ratio 2.06
Quick Ratio ranked higher than
59.20% of 250 companies
in the Diagnostics & Research industry.
Industry Max: 97.84, Med: 2.14, Min: 0.02
PACB: 2.06
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.92, Med: 4.68, Max: 22.74
Current: 2.06
1.92
22.74
Days Inventory 147.45
Days Inventory ranked lower than
63.24% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 917.88, Med: 79.76, Min: 0.37
PACB: 147.45
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 103.43, Med: 129.84, Max: 196.1
Current: 147.45
103.43
196.1
Days Sales Outstanding 35.10
Days Sales Outstanding ranked higher than
66.18% of 204 companies
in the Diagnostics & Research industry.
Industry Max: 521.64, Med: 67.51, Min: 1
PACB: 35.1
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 20.52, Med: 39.9, Max: 74.35
Current: 35.1
20.52
74.35
Days Payable 60.45
Days Payable ranked lower than
55.61% of 187 companies
in the Diagnostics & Research industry.
Industry Max: 981.81, Med: 63.34, Min: 1
PACB: 60.45
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 28.8, Med: 50.49, Max: 83.1
Current: 60.45
28.8
83.1

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -23.10
3-Year Share Buyback Rate ranked lower than
64.44% of 180 companies
in the Diagnostics & Research industry.
Industry Max: 3.4, Med: -7.9, Min: -1732.6
PACB: -23.1
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -380.3, Med: -14.4, Max: -7.8
Current: -23.1
-380.3
-7.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 10.97
Price-to-Tangible-Book ranked higher than
70.05% of 207 companies
in the Diagnostics & Research industry.
Industry Max: 272.36, Med: 6.46, Min: 0.21
PACB: 10.97
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.8, Med: 5, Max: 14.29
Current: 10.97
0.8
14.29
Price-to-Median-PS-Value 1.86
Price-to-Median-PS-Value ranked higher than
86.53% of 193 companies
in the Diagnostics & Research industry.
Industry Max: 7.22, Med: 1.01, Min: 0.01
PACB: 1.86
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.38, Med: 0.94, Max: 4.01
Current: 1.86
0.38
4.01
Earnings Yield (Joel Greenblatt) % -10.76
Earnings Yield (Greenblatt) ranked lower than
87.92% of 265 companies
in the Diagnostics & Research industry.
Industry Max: 17.42, Med: -0.98, Min: -1428.57
PACB: -10.76
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -3441.4, Med: -19.6, Max: 26741.7
Current: -10.76
-3441.4
26741.7

More Statistics

Revenue (TTM) (Mil) $ 75.69
EPS (TTM) $ -0.77
Beta 1.03
Volatility % 89.25
52-Week Range $ 2.44 - 7.84
Shares Outstanding (Mil) 152.67

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 2
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N